Lunit Inc. (KOSDAQ:328130)
South Korea · Delayed Price · Currency is KRW 8,300.00
+90.00 (1.10%)
Sep 17, 2026, 3:30 PM KST
Lunit Revenue
Lunit had revenue of 21.81B KRW in the quarter ending June 30, 2026, with 22.04% growth. This brings the company's revenue in the last twelve months to 91.82B, up 24.27% year-over-year. In the year 2025, Lunit had annual revenue of 83.13B with 53.43% growth.
Revenue (ttm)
91.82B
Revenue Growth
+24.27%
P/S Ratio
6.66
Revenue / Employee
n/a
Employees
n/a
Market Cap
611.30B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 83.13B | 28.95B | 53.43% |
| Dec 31, 2024 | 54.18B | 29.10B | 116.03% |
| Dec 31, 2023 | 25.08B | 11.21B | 80.88% |
| Dec 31, 2022 | 13.87B | 7.23B | 108.85% |
| Dec 31, 2021 | 6.64B | 5.21B | 364.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Dong-A Socio Holdings | 1.52T |
| Samsung Epis Holdings | 1.51T |
| JW Pharmaceutical | 820.86B |
| Myung In Pharmaceutical LTD. | 293.03B |
| ALTEOGEN | 254.01B |
| Onconic Therapeutics | 82.17B |